Spruce Biosciences is a development-stage drugmaker, so its analyst coverage is thin but active, and targets differ dramatically because each firm is modeling a different probability of clinical success and future dilution. Reviewing roughly nine to ten recent, individually attributed price targets, the range spans from about $104 on the low end to $230 on the high end — a wide spread of roughly $126 that underscores genuine disagreement rather than a tight consensus.
Recent actions illustrate the mix. Lake Street initiated coverage with a Buy and a $149 target in September 2026, while Citizens reiterated a Market Outperform with a $144 target the same month and Craig-Hallum maintained a Buy at $140. On the high end, Oppenheimer has carried a $230 target, while B. Riley has set $160. On the cautious side, Leerink Partners lowered its target to $120, and H.C. Wainwright trimmed at least one target toward $104. Averaging these recent figures produces a mean in the upper-$140s, which rounds to the $150 central target used here.
This $150 figure is a calculated average of verified targets, not an official published consensus, and it should be read alongside the wide low-to-high range rather than as a precise destination.
With SPRB trading around $49 — against a 52-week range of roughly $38 to $129 — reaching $150 would require a gain of about 200%. That is a very large move by any standard, and it would take the stock materially above its prior 52-week high.
The path would almost certainly hinge on company-specific catalysts rather than broad sector drift. Spruce is a micro-cap with a market capitalization near $140 million and essentially no product revenue, so valuation is driven by the perceived probability that its lead program, tildacerfont, can clear clinical and regulatory hurdles. A single positive data readout, partnership payment, or financing event has historically produced outsized moves in this stock, which carries a beta of roughly 3.5.
Several factors could underpin upside. The company holds a net cash position of roughly $80 million, or more than $27 per share — more than half the current share price — which limits near-term dilution risk relative to many peers. Most covering analysts maintain Buy or equivalent ratings, suggesting the research community sees value well above current levels. A heavy short interest (roughly 18% of shares outstanding) can also amplify upward moves if positive news forces short covering. Finally, any clinical or regulatory progress on tildacerfont or an expanded partnership could materially reset the market's probability assessment of the pipeline.
The obstacles are equally concrete. Spruce continues to report significant net losses, and its most recent quarterly result missed expectations, with GAAP EPS (earnings per share) of roughly -$8.51 versus a consensus estimate near -$5.76. Development-stage companies often require additional capital, and future share issuance would dilute existing holders. Clinical trials carry a high risk of failure, and a disappointing readout could compress the stock quickly. The extremely wide analyst range — with some targets below $110 — reflects the real possibility that the market assigns a lower value to the pipeline than the most bullish models do.
From a technical standpoint, $150 sits above the stock's prior 52-week high near $129, meaning there is little established overhead supply between that level and the target. On the downside, the 52-week low near $38 and the 50-day moving average near $48 represent reference points. The stock's elevated beta and wide daily ranges indicate a thin, volatile tape where large percentage swings are common, so conventional support and resistance should be treated as approximate zones rather than precise levels.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may use shorter or longer windows, and targets for clinical-stage companies often embed assumptions about specific data events. Investors should monitor quarterly earnings and cash burn, any clinical readouts or regulatory updates for tildacerfont, analyst target revisions (which have been frequent and occasionally sharp), and any financing or partnership announcements. Changes in short interest and institutional positioning are also worth watching given the stock's structure.
For traders tracking volatile, news-driven names like Spruce Biosciences, Tickeron's AI Daily Buy/Sell Signals offer an additional, data-driven lens. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone allows.
The central $150 target — the rounded average of recent analyst price targets — implies roughly 200% upside from a price near $49, a very large move that is plausible only under an optimistic clinical and financing scenario. The strongest supports are the net-cash balance sheet, the predominantly bullish analyst posture, and the potential for short-covering on positive catalysts; the principal obstacles are recurring losses, a recent earnings miss, dilution risk, and the genuine uncertainty embedded in a wide $104-to-$230 target range. The wide disagreement among analysts is itself the key signal: this is a high-risk, high-volatility name where the outcome will be determined by data and capital decisions rather than by the average target. Investors should monitor clinical updates, cash position, analyst revisions, and any new financing before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with MLEC. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then MLEC could also see price increases.
| Ticker / NAME | Correlation To SPRB | 1D Price Change % | ||
|---|---|---|---|---|
| SPRB | 100% | -5.42% | ||
| MLEC - SPRB | 51% Loosely correlated | N/A | ||
| ANRO - SPRB | 37% Loosely correlated | +2.91% | ||
| COYA - SPRB | 37% Loosely correlated | -5.11% | ||
| FLNA - SPRB | 36% Loosely correlated | -2.03% | ||
| CMMB - SPRB | 35% Loosely correlated | +2.67% | ||
More | ||||